Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.78 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16179916 | 0.97 | KCNK3 (0.79) | KCNK3KCNK9SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL2740433 | 0.90 | KCNK3 (0.73) | KCNK3KCNK9SMN1; SMN2MAPTMEN1 | |
| SCHEMBL23011772 | 0.87 | KCNK3 (0.82) | KCNK3KCNK9SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20043009 | 0.84 | KCNK3 (0.72) | KCNK3KCNK9SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL30368959 | 0.84 | KCNK3 (0.72) | KCNK3KCNK9SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL30556345 | 0.84 | KCNK3 (0.72) | KCNK3KCNK9SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13870834 | 0.83 | KCNK3 (0.70) | KCNK3KCNK9SMN1; SMN2MAPTMEN1 | |
| SCHEMBL11729204 | 0.83 | MEN1 (0.80) | SMN1; SMN2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL1929165 | 0.82 | NPC1 (0.85) | KCNK3KCNK9SMN1; SMN2MAPTMEN1 | |
| SCHEMBL29684351 | 0.82 | KCNK3 (0.74) | KCNK3KCNK9SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2021042410-A1 | SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110627767-B | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-110627767-A | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-31 | — | — | CN | disclosed |
| US-4439444-A | HISTAMINE RECEPTOR ANTAGONISTS | SANOFI (FR) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | KCNK3 1980/4885KCNK9 545/4885SMN1; SMN2 133/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | KCNK3 2135/4885KCNK9 679/4885SMN1; SMN2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.